COMPANY

ALX Oncology

HQ: South San Francisco, CA source · alxoncology.com ↗ · West Coast

Keywords: oncology immuno-oncology Head and Neck Cancer Head and Neck Squamous Cell Carcinoma NSCLC (Advanced Non-small Cell Lung Cancer) HNSCC CRC (Colorectal Cancer) Colo-rectal Cancer Esophageal Squamous Cell Carcinoma Metastatic Breast Cancer Gastric Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma NonHodgkin Lymphoma Bladder Cancer Urothelial Carcinoma Higher Risk Myelodysplastic Syndromes Acute Myeloid Leukemia Adult AML ALX2004 Evorpacept (ALX148)

Location: South San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$150.0MRaised (2 yrs)9Trials (company is sponsor)

Timeline

Jan 30, 2026 Raise Follow-on offering: $150M (total, as published), announced Jan 30, 2026. Source: SEC filing. source ↗
Dec 10, 2025 Trial start Phase 2: ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer source ↗
Aug 18, 2025 Trial start Phase 1: A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors source ↗
Nov 2, 2022 Trial start Phase 1: A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) source ↗
Jan 15, 2022 Trial start Phase 2/Phase 3: A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) source ↗
May 10, 2021 Trial start Phase 2: Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) source ↗
May 5, 2021 Trial start Phase 1: A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) source ↗
Apr 2, 2021 Trial start Phase 2: Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) source ↗
Oct 2, 2020 Trial start Phase 1: A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) source ↗
Feb 3, 2017 Trial start Phase 1: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) source ↗

Upcoming milestones

2027-06 (ESTIMATED) · Phase 1 · A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors · NCT07085091
2027-12 (ESTIMATED) · Phase 2 · ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · NCT07007559

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $150.0M. Last 2 years.

Jan 30, 2026 Follow-on offering: $150M (total, as published), announced Jan 30, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT07085091	A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors	Phase 1	Recruiting	Aug 18, 2025	2027-06 (estimated)
NCT07007559	ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer	Phase 2	Recruiting	Dec 10, 2025	2027-12 (estimated)
NCT05002127	A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)	Phase 2/Phase 3	Active, not recruiting	Jan 15, 2022	May 24, 2024 (actual)
NCT04675333	Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)	Phase 2	Active, not recruiting	May 10, 2021	Mar 3, 2025 (actual)
NCT04675294	Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)	Phase 2	Active, not recruiting	Apr 2, 2021	Mar 3, 2025 (actual)
NCT03013218	A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)	Phase 1	Completed	Feb 3, 2017	Feb 1, 2022 (actual)
NCT05524545	A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)	Phase 1	Completed	Nov 2, 2022	Jun 27, 2025 (actual)
NCT04417517	A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)	Phase 1	Terminated	Oct 2, 2020	Jan 17, 2025 (actual)
NCT04755244	A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)	Phase 1	Terminated	May 5, 2021	May 5, 2023 (actual)